Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INKmune in metastatic castration-resistant prostate cancer
NCT06056791Phase 2Completed
- Sponsor
- INmune Bio Inc.
- Start
- Nov 2023
- Primary completion
- Sep 2025
- Modality
- Whole Cell Cancer Vaccines, Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
A Phase 2 trial of INKmune in metastatic castration-resistant prostate cancer (mCRPC), sponsored by INmune Bio Inc.. Started Nov 2023; status: completed.
02
Drugs
INKmune
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06056791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06056791.